Clinical Data

To ensure the reproducibility and reliability of the Eeva™ Test, Auxogyn applied rigorous standards for clinical validation. In a multi-center, prospective clinical trial of 54 patients with approximately 758 embryos, adjunctive use of Eeva was found to be:

Safe and effective.
Highly informative in identifying embryos that will develop to the blastocyst stage.
- The overall odds ratio* for the adjunctive use of Eeva with traditional morphology was 2.57 and highly statistically significant (p<0.0001).
- The overall odds ratio for traditional morphology alone was 1.68 and was also statistically significant (p<0.0001).¹

The specificity for the adjunctive use of the Eeva Test with traditional morphology was 76%, compared to the specificity of traditional morphology alone, which was 39%¹.
Highly consistent among diverse embryologists
- Operator performance variability was reduced with adjunctive use of the Eeva Test compared to traditional morphology grading.^1,2
- Every embryologist benefitted from adjunct use of Eeva
- Improved consistency of embryo selection

Additional scientific and clinical research studies are underway to further the advancement of non-invasive assays that will provide IVF clinicians and their patients with quantifiable information about the health of their embryos. The continuing goal of Auxogyn’s research is to improve fundamental understanding of early in vitro human development and provide sound scientific and clinical evidence to positively impact clinical care in reproductive health.

Odds ratio is a measure of association between an exposure and an outcome. The OR represents the odds that an outcome will occur given a particular exposure, compared to the odds of the outcome occurring in the absence of that exposure.

OR=1 Exposure does not affect odds of outcome

OR>1 Exposure associated with higher odds of outcome

OR<1 Exposure associated with lower odds of outcome

Data on file at Auxogyn.
Conaghan et al. Fertility & Sterility (2013)